94

Theraclion SAMUN Theraclion Stock Report

Last reporting period 31 Dec, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.02

Micro

Exchange

XMUN - Boerse Muenchen

941.MU Stock Analysis

94

Uncovered

Theraclion SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-10/100

Low score

Market cap $B

0.02

Dividend yield

Shares outstanding

29.597 B

Théraclion SA develops, manufactures, and markets oncological medical equipment. The company is headquartered in Malakoff, Ile-De-France. The company went IPO on 2014-04-25. The firm is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The firm provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.

View Section: Eyestock Rating